Phase 1 First-in-Human Single Ascending Dose Study of PLX5622 in Healthy Adult Volunteers
Healthy
Enrolment: 32 · Results not recorded
Loading the evidence…
Drug · Macrophage colony stimulating factor receptor inhibitor
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Healthy
Enrolment: 32 · Results not recorded
Rheumatoid Arthritis
Enrolment: 26 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Midline fluid percussion injury (diffuse TBI)
Microglial elimination by PLX5622 did not affect cortical neuron axotomy induced by TBI, but attenuated rod microglial formation and astrogliosis and prevented both acute and chronic cortical inflammatory gene responses.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.82. Machine-extracted fields require source verification.
Model: Optic nerve crush, with lens injury used as a regeneration-enhancing conditioning lesion
PLX5622 eliminated virtually all microglia yet retinal ganglion cell degeneration, regeneration-associated gene induction and axon regeneration were unaffected; only clearance of dead retinal ganglion cells was impaired and astrocyte repopulation delayed, while concurrent microglia and macrophage d…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.66. Machine-extracted fields require source verification.